News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Abbott Laboratories' stock has dropped 16.4% over the past year, but a Discounted Cash Flow (DCF) analysis suggests a 28.1% upside compared to its current share price, indicating it's undervalued based on future cash flow potential. However, its P/E ratio of 34.6x is higher …
Sharemaestro market context Price above Trend Line 52 weeks -22.2% · Next-week setup negative 43.2%Abbott Laboratories HQ photo- by Sundry Photography via iStock Lake County, Illinois-based Abbott Laboratories (ABT) discovers, develops, manufactures, and sells health care products worldwide. The company has a market cap of $182.9 billion and operates through Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and …
This article lists several ETFs that hold BridgeBio Oncology Therapeutics, Inc. (BBOT) stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price change, and NAV total return. The ETFs highlighted primarily focus on the healthcare and biotechnology sectors, offering …
This article compares Abbott Laboratories (ABT) and Danaher Corporation (DHR) following their recent Q2 2026 earnings reports. Abbott showcased strong performance driven by its diagnostics and medical devices segments, leading to an increased annual profit forecast and positive analyst sentiment. Danaher, while showing core …
Abbott Laboratories (ABT) stock declined by 1.55% on Tuesday, closing at $105.46. This underperformance occurred on a day when the broader market, including the S&P 500 and Dow Jones Industrial Average, saw significant gains. The stock's fall ended a two-day winning streak for Abbott …
Abbott Laboratories (ABT) stock increased by 1.34% to $107.12 on Monday, marking its second consecutive day of gains. Despite this rise, the stock underperformed the broader market, as the S&P 500 Index rose by 1.48% and the Dow Jones Industrial Average gained 1.32% on …
Abbott Laboratories has seen its stock decline by 16% this year, despite five consecutive adjusted EPS beats, primarily due to the financial impact of its $21 billion Exact Sciences acquisition. While the market reacted negatively to GAAP earnings, analysts like Barclays' Matt Miksic see …
* Matrix Asset Advisors' Large Cap Value Portfolio gained in the mid-teens in Q2 2026, roughly in line with the S&P 500, which returned 15.2% and modestly ahead of the Russell 1000 Value Index. * The firm initiated new positions in Abbott Laboratories (NYSE: …
Choosing between Abbott Laboratories (NYSE:ABT) and Eli Lilly (NYSE:LLY) involves weighing the steady diversification of a healthcare conglomerate against the high-velocity expansion of a pharmaceutical leader. Both companies represent different investment profiles. Abbott operates as a diversified healthcare giant with interests ranging from infant …
Abbott Laboratories' stock has dropped 15% over the past year, and a Discounted Cash Flow (DCF) analysis suggests it is undervalued by 28.9%, with an intrinsic value of about $149 per share. However, its P/E ratio of 33.9x is higher than the industry average, …
Sharemaestro market context Price above Trend Line 52 weeks -14.8% · Next-week setup positive 55.5%This article examines three dividend stocks—Abbott Laboratories (ABT), Consolidated Water (
On Thursday, Abbott Laboratories (ABT) shares fell by 2.21% to $105.61, despite a strong trading session for the broader market with both the S&P 500 and Dow Jones Industrial Average rising. This decline ended a six-day winning streak for the stock.
Abbott Laboratories reported mixed Q2 2026 results with increased sales but lower net income and diluted EPS. Despite this, the company's stock rose 7.4% due to strengthening its medical device and diagnostics portfolio, including a significant real-world TriClip heart valve study and expansion in …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%AbbVie (NYSE: ABBV), one of the world's largest pharmaceutical companies, is usually considered a blue chip dividend stock rather than a higher-growth one. Yet over the past five years, its stock has rallied 125% and delivered a total return of 170% with reinvested dividends. …
This article details the shareholder structure of Abbott Laboratories (ABT), listing its major shareholders and institutional holdings. It provides a breakdown of the largest individual shareholders like Vanguard and BlackRock, as well as categorizes shareholder types such as investment advisors and pension funds. The …
UBS has revised its price target for Abbott Laboratories (ABT) to $125, down from the previous $135, while reiterating a Buy rating on the stock. This adjustment reflects a moderated outlook but continues to signal confidence in the company's performance. The stock's current performance …
Abbott Laboratories is focusing on continuous glucose monitoring, oncology diagnostics, and advanced cardiovascular treatment as key innovation themes for long-term growth. The company has seen strong sales in these areas, including its FreeStyle Libre, despite facing risks like reimbursement challenges, integration demands from acquisitions, …
The article focuses on BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) and its revenue breakdown, accessible through TradingView's financial section. It provides an overview of market data, fundamentals, and statistics for the company. The content appears to be a stub or a navigation page within …
Freenome Inc. has received FDA approval for its SimpleScreen CRC, a blood test for early detection of colorectal cancer, which will be marketed by Abbott starting this fall. This marks a significant achievement for the company, following its public offering for $300 million.
The Northern District of Illinois ruled that Abbott Laboratories did not commit securities fraud regarding its tainted baby formula. This decision indicates that the allegations did not meet the legal threshold for securities fraud. The case was brought against the company concerning the public …
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) has secured exclusive U.S. commercialization rights for Freenome's SimpleScreen CRC, a newly FDA approved blood based colorectal cancer screening test. …
Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Abbott Laboratories (ABT) experienced a decline in performance in Q2 2026, primarily due to lowered full-year guidance after the Exact Sciences acquisition, headwinds in its Nutrition and Diagnostics segments, and ongoing litigation concerns related to its preterm infant formula. These issues overshadowed strong organic …
Abbott Laboratories (ABT) reported a stronger second quarter with an earnings beat and raised its full-year profit outlook, driven by growth in medical devices and cancer diagnostics. Despite these positive updates and a diversified business model providing support, the stock's valuation offers limited upside …
This Zacks Investment Ideas feature highlights General Motors, Abbott Laboratories, and Johnson & Johnson, all of which posted strong Q2 earnings and raised their guidance. These guidance upgrades are considered a bullish indicator, often leading to positive share reactions and reflecting improving business fundamentals, …
Octagon Capital Advisors LP has reduced its stake in BridgeBio Oncology Therapeutics (NASDAQ:BBOT) by 31.1%, selling 324,110 shares but still holding 719,000 shares valued at approximately $6.44 million. Despite institutional selling, analysts generally maintain a "Moderate Buy" rating with an average price target of …
The article provides an overview of institutional confidence in BridgeBio Oncology Therapeutics Ord Shs (BBOT) by listing the top institutional shareholders and their shareholdings. It details the number of shares held by major investment firms such as Cormorant Asset Management, BridgeBio Pharma, and Deerfield …
The article provides an earnings forecast for BridgeBio Oncology Therapeutics Ord Shs (BBOT), highlighting analyst ratings, target price, and expected EPS and revenue growth. Based on 11 analysts, the stock has a "Buy" trend with a significant upside space. The document also includes a …
Abbott Laboratories' stock (ABT) is trading steadily, supported by diversified revenue streams from diagnostics, medical devices, nutrition, and established pharmaceuticals. Despite a decline in COVID-19 testing revenue, core businesses like continuous glucose monitoring and cardiovascular devices are driving growth, leading to resilient earnings and …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Granahan Investment Management LLC has acquired 231,040 shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) during the first quarter, now holding a 0.29% stake valued at approximately $2.07 million. Other institutional investors have also increased their positions, with hedge funds and institutions collectively owning 54.89% of …
This article provides a detailed financial overview of BridgeBio Oncology Therapeutics Ord Shs (BBOT), including its current stock price, market capitalization, P/E ratio, and recent performance. It also covers analyst ratings, key indicators, major shareholders, and comparisons with peer companies in the pharmaceutical sector. …
Search by ticker symbol or company name and select a result to open its chart.